AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio

AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent

Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases

AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association International Conference

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study

Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.

Here's Why AC Immune Jumped Higher Today

AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients.

AC Immune Stock Catapults To Two-Year High On Alzheimer's News

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company.

AC Immune Surges Higher On Alzheimer's Trial Update

Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study

AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study

Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool

Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy

LAUSANNE, Switzerland, June  26, 2020  (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced AC Immune shareholders approved all of the resolutions as proposed by the Board of Directors at today's Annual General Meeting (AGM) in Lausanne. At the AGM, shareholders re-elected Douglas Williams, Martin Velasco, Peter Bollmann, Andrea Pfeifer, Thomas Graney, Werner Lanthaler and Roy Twyman to their positions on the Board of Directors. Douglas Williams and Martin Velasco will continue to serve as Chairman and Vice-Chairman of the Board, respectively.   Douglas Williams, Chairman of the Board, said: “The Company is gathering momentum on the back of strong progress, and we remain on track to meet multiple value-creating milestones this year with five clinical readouts expected in 2020. We are especially excited about the Phase 2 trial evaluating our anti-Tau antibody semorinemab in Alzheimer’s disease. The primary completion of the trial is expected soon and we expect top line data in the second half of 2020. We are also extremely pleased to report AC Immune’s solid financial position, with operations fully funded through at least Q1 2024.” AC Immune has always maintained a robust business continuity plan. During the Covid-19 outbreak, every provision has been made to protect the health of patients, staff and investigators, as well as the productivity and integrity of our clinical development. Importantly, we currently remain on track to deliver all clinical and preclinical readouts expected in 2020. The Swiss Government’s management of Covid-19 means that businesses have been able to return to near normal working practices with all AC Immune staff now back on site in Lausanne.  As part of its efforts to ensure stakeholder safety during the Covid-19 outbreak, AC Immune held only the mandatory part of the AGM as stipulated by Swiss law and by the Company’s Articles of Association. Voting took place via the independent proxy.  About AC Immune SA  AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Eli Lilly and Company and Janssen Pharmaceuticals.

AC Immune Announces Results of Annual General Meeting

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

Latest appointment further reinforces the depth and breadth of the Company’s clinical development competences in Down syndrome-related Alzheimer’s disease Latest appointment further reinforces the depth and breadth of the Company’s clinical development competences in Down syndrome-related Alzheimer’s disease

Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immune’s Clinical Advisory Board

Agilysys

American Express

Top Ranked Momentum Stocks to Buy for January 30th

Ascendis Pharma

Eyenovia

Ngm Biopharmaceuticals Inc

SAGE Therapeutics

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?

LAUSANNE, Switzerland, Oct.  24, 2019  (GLOBE NEWSWIRE) --  AC Immune SA  (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it will host a key opinion leader (KOL) meeting focused on pathological Tau protein as a therapeutic target and diagnostic biomarker for Alzheimer’s and other neurodegenerative diseases. The event will take place in New York City on Wednesday, November 6, 2019.

AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

Intra-Cellular Therapies

vTv Therapeutics

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

Lilly to pay CHF30 million development milestone

AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer’s and  neurodegenerative diseases

AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620

Company to Give an Oral Presentation at Michael J. Fox Foundation’s 13th Annual Parkinson’s Disease Therapeutics Conference Company to Give an Oral Presentation at Michael J. Fox Foundation’s 13th Annual Parkinson’s Disease Therapeutics Conference

AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson’s Disease Diagnostic Imaging Agent

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

AC Immune Initiates Phase I Study for Alzheimer's Disease

Alzheimer's disease is the devastating threat of modern era.

AC Immune - Light In The End Of Tunnel?

AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates

AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for AC Immune Stock (ACIU)